I NTRO D U C TIO N
Juvenile idiopathic arthritis (JIA) is a group of disorders with onset in children below 16 years of age, clinically manifesting as arthritis of no known aetiology lasting at least six weeks. Despite being a diagnosis of exclusion, JIA is still the most common rheumatologic disease and cause of chronic arthritis in children worldwide, with an annual incidence ranging from 0.8 to 22.6/100,000 children, and a prevalence ranging from 7 to 401/100,000. (1) The International League of Associations for Rheumatology has published on a classification system for the different forms of JIA. (2) In a 1998 Singaporean study, JIA accounted for 28.8%
of all rheumatologic conditions, second to systemic lupus erythematosus (51.8%). (3) According to a registry established to study the epidemiological and disease features of JIA in Singapore, enthesitis-related JIA is predominant in the local population. (4) According to the American College of Rheumatology (ACR) clinical guidelines, (5) intra-articular glucocorticoids (IAGs) are recommended as the first-line therapy for oligoarticular JIA, except in cases of very mild oligoarticular JIA with low disease activity and no features of poor prognosis, where a twomonth trial of nonsteroidal anti-inflammatory drugs (NSAIDs) monotherapy may be administered. IAGs can also serve as an adjunct to systemic therapy in more severe forms of JIA to avoid increasing the dose of systemic agents, or for temporary patient relief while awaiting the effects of systemic agents. (6) The benefits of IAGs are well described, including the rapid resolution of synovitis, provision of pain relief, aiding return to normal function, and reduction of complications of oligoarthritis such as leg length discrepancy. (7) It has been found that the use of intra-articular triamcinolone hexacetonide (TH) injections with methotrexate is associated with longer remission periods. (8) A study of 21 patients who underwent gadoliniumenhanced magnetic resonance imaging after IAG injections found improvements in inflammation and pannus formation, with no deleterious effects on articular cartilage. (9) (12) Studies on the effects of postinjection rest (i.e. immobilisation, reduced activity or splinting) have been inconsistent. A 1994 study suggested that 24-hour bed rest was associated with longer periods of clinical response of the knee to IAG injections. (13) However, other separate studies on 48-hour post-IAG immobilisation of the wrist and elbow joints showed no statistical difference in clinical response between immobilised joints and those that returned to normal activity. (14, 15) It has been suggested that weight-bearing joints benefit morefrom postinjection rest. (14) Generally, 24-hour postinjection rest is recommended. (16) Complications associated with IAG are uncommon and mainly localised. Of these, the most notable are cutaneous hypopigmentation and subcutaneous atrophy. The former is associated with repeated injections and darker skin, and though cutaneous hypopigmentation usually resolves in two months, it can also be permanent. The latter complication likely occurs due to leakage of the injected glucocorticoid compound into the skin, and is associated with injections of smaller joints and higher volumes and doses of glucocorticoids. (17) The incidence of such cutaneous side effects was found to be 2% in one 1990 study, and 8.3% in another 2011 study. (18, 19) Other risks include intra-articular calcifications, which was found to occur in 4.9% in the same aforementioned 1990 study, (19) periarticular calcifications, injury to surrounding structures and haemorrhage.
Septic arthritis, while a worrisome complication, is rare and estimated by one study to occur in 1/10,000 injections, (20) and 4.6/100,000 in another. (21) An Icelandic study found a septic arthritis incidence of 0.037% in patients post arthrocentesis. (22) Avascular necrosis (AVN) has been found to occur rarely in children with JIA receiving IAG. A retrospective study reported one case of hip necrosis out of 1,439 IAG injections. (23) Another study reported three incidents of femoral head necrosis out of 67 IAG injections. However, these cases were found exclusively in the context of concurrent systemic corticosteroids, (24) thereby making it difficult to strictly determine IAG as the cause of femoral head AVN.
Using a retrospective chart review, the present study examined the efficacy and safety of IAG injections in our population of patients with JIA treated at National University Hospital, Singapore. (Table II) . Of the 26 IAG injections administered, 21 were single injections (i.e. after which patients did not need to return for repeat injections) ( Table III) . Out of these 26 injections, 5 were repeat injections -3 were administered to separate knee joints, 1 to an ankle joint and 1 to a fifth metacarpophalangeal joint. The three knee injections had a mean interval of nine months between repeated injections, while the intervals between IAG injections to the ankle and fifth metacarpophalangeal joints were eight and four months, respectively.
M E TH O DS
Aseptic protocol was adhered to for all IAG injections.
Sterile sets were used for each injection, the injection sites were cleaned with either iodine or chlorhexidine with 70% alcohol, and the fields were draped with a sterile towel. Sterile gloves were worn by the doctor performing the procedure, and care was taken to maintain sterility throughout the procedure. Verbal consent was obtained from all ten patients, complete with explanation of the procedure's purpose, risks, steps and expected outcome. All patients were given information leaflets during the consultation, which advised minimising activity for 24-48 hours after the procedure, taking the prescribed oral analgesia as needed for two to three days, keeping the injection wound clean and dry, using ice packs to reduce any inflammation of the injection site, looking out for red flags that may indicate infection and keeping to the arranged follow-up appointment, and also included information on how to contact the department for help if necessary.
In our study, we found that out of 22 injections with the necessary follow-up data, three were complicated by cutaneous side effects within six months of the injections. These injections were made to an ankle joint, a first metatarsophalangeal joint and a wrist joint. The wrist joint was noted to have circular subcutaneous atrophy of 1 cm in diameter at the injection site.
The other two joints featured hypopigmented macules over the injection sites, which are relatively less disfiguring than subcutaneous atrophy. Otherwise, apart from one patient who had postinjection pain lasting for one day, no other negative complaints were received and no major complications such as septic arthritis or avascular necrosis arose.
All IAG injections performed were documented in the case notes, and the drug and dosage used were recorded either on the case notes or in an electronic patient database. Joint approaches for 12 out of 26 injections were not noted down. The mean interval between repeat injections across all joints was fairly satisfactory at 7.8 months. It appears that injections to the knee joint fared the best, with the interval between repeat injections being an average of nine months in our patient group.
D I SCU S S IO N
While length of remission of symptoms in the joint or time to next required injection can be used to gauge response to IAG, (26) there are many confounding factors such as the addition of systemic medications, the category of JIA, the duration of disease before the injection and injection accuracy. (17) As (17) A study conducted on 38 children receiving ultrasonography-guided subtalar steroid injections found hypopigmentation in 53% of the patients. (27) This was thought to be due to leakage along the 
In the present study, medical documentation was inadequate.
More attention should have been paid to this, as better documentation would facilitate closer monitoring of disease progression or remission. It should be noted that the necessity of written consent was not yet standardised for intra-articular injections at the time the injections in this study were performed.
This was also the case for other procedures, such as lumbar punctures. However, it is now recognised that all such procedures, require proper written consent. Our centre's practice has over the past two years shifted from obtaining merely verbal consent to written consent without exception.
In conclusion, we found that patients with JIA treated at our institution safely underwent IAG injections, which are a useful first-line treatment and adjunct treatment in oligoarticular JIA and other types of JIA, respectively.
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